関与物質
| 役割 | 名称 | HCID | 仕込み量 |
|---|
| 反応物 | 3-Bromopyridine | HCID 12286 | — |
| 反応物 | tert-Butyl piperazine-1-carboxylate | HCID 143452 | — |
| 試薬 | Sodium t-butoxide | HCID 23676156 | — |
| 触媒 | Palladium (II) acetate | HCID 4144353 | — |
| 触媒 | 2-Dicyclohexylphosphino-2',6'-diisopropoxybiphenyl | HCID 16217985 | — |
| 溶媒 | 1,4-Dioxane | HCID 31275 | — |
| 生成物 | Tert-butyl 4-(pyridin-3-YL)piperazine-1-carboxylate | HCID 11673373 | 37.96% |
反応手順
diacetoxypalladium (0.072 g, 0.32 mmol) and RuPhos (0.301 g, 0.64 mmol) were stirred in 1,4-dioxane (11.36 ml) for 10 mins at 50 °C.tert-butyl piperazine-1-carboxylate (0.6 g, 3.22 mmol), 3-bromopyridine (0.310 ml, 3.22 mmol) and sodium tert-butoxide (0.464 g, 4.83 mmol) were added and the reaction mixture was stirred at 100 °C for 64 h. The reaction mixture was filtered through celite. The crude product was purified by flash silica chromatography, elution gradient 20 to 100% EtOAc in heptane. Pure fractions were evaporated to dryness to afford tert-butyl 4-(pyridin-3-yl)piperazine-1-carboxylate (0.322 g, 38.0 %) as a yellow oil which crystallised on standing. This was then combined with EN06111-39-01.
情報源と証拠
| 出典データセット | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-c9d3e32c4ae3434fab0938e5982b9ebd |
|---|
| 出典メモ | 750 AstraZeneca ELN dataset |
|---|